首页|胰高血糖素样肽-1受体激动剂类药物疗效及在减重代谢外科中的应用

胰高血糖素样肽-1受体激动剂类药物疗效及在减重代谢外科中的应用

扫码查看
目前,超重和肥胖症患病率增长迅速.减重代谢手术是治疗肥胖及相关合并症的有效手段,但仅少数肥胖症患者接受减重代谢手术,大部分患者选择药物减肥.新兴药物胰高糖素样肽-1受体激动剂(GLP-1RA)对超重和肥胖症患者疗效显著,可作为减重代谢手术的有益补充,给减重代谢外科带来深远影响.笔者全面回顾GLP-1RA类药物的应用进展,并深入阐述其在减重代谢外科中应用.
Efficacy of glucagon-like peptide-1 receptor agonists and its application in bariatric and meta-bolic surgery
At present,the prevalence of overweight and obesity is increasing rapidly.Baria-tric and metabolic surgery is an effective means to treat obesity and related comorbidities,but only a few obesity patients have received bariatric surgery,and most patients choose to accept drugs to lose weight.Glucagon-like peptide-1 receptor agonists(GLP-1RA),as an emerging drug,has a signi-ficant effect on overweight and obesity patients,and can be used as a beneficial supplement for bariatric surgery,which has a profound impact on bariatric surgery.Based on the relevant literature,the authors discuss the application and influence of GLP-1RA in bariatric and metabolic surgery.

ObesityBariatric metabolic surgeryWeight-loss drugsGlucagon-like peptide-1 receptor agonistApplication

王存川、马庆阳、陈文辉

展开 >

暨南大学附属第一医院肥胖与代谢病外科,广州 510630

肥胖症 减重代谢手术 减肥药物 胰高糖素样肽-1受体激动剂 应用

2024

中华消化外科杂志
中华医学会

中华消化外科杂志

CSTPCD北大核心
影响因子:1.899
ISSN:1673-9752
年,卷(期):2024.23(8)